| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2016 | FY2016 | FY2016 | FY2015 | FY2015 | FY2015 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71K-97.6% | $3.0M+22.1% | $2.5M+550.4% | $377K | |||||||||||||
| Cost of revenue | $218K-95.5% | $4.8M-24.6% | $6.4M+77.6% | $3.6M | |||||||||||||
| Sales and marketing | $917K-92.1% | $11.6M-33.9% | $17.6M-9.0% | $19.3M | |||||||||||||
| General and administrative | $16.3M-33.7% | $24.5M-20.8% | $30.9M-25.3% | $41.4M | |||||||||||||
| Amortization of acquired intangible assets | $0-100.0% | $559K-72.3% | $2.0M+13.3% | $1.8M | |||||||||||||
| Research and development | $4.5M-24.3% | $5.9M-58.4% | $14.3M-43.7% | $25.3M | |||||||||||||
| Total operating expenses | $21.9M-53.9% | $47.5M-33.4% | $71.2M-22.1% | $91.5M | |||||||||||||
| Operating loss | -$21.8M+51.0% | -$44.5M+35.3% | -$68.8M+24.5% | -$91.1M | |||||||||||||
| Interest income | $29K-88.6% | $254K-49.7% | $505K+198.8% | $169K | |||||||||||||
| Interest expense | -$21K+53.3% | -$45K+92.4% | -$589K+54.0% | -$1.3M | |||||||||||||
| Gain on deconsolidation of subsidiary | $0-100.0% | $72.3M | — | — | |||||||||||||
| Change in fair value - equity method investment | $8.5M+1494.5% | $532K | — | — | |||||||||||||
| Change in fair value - Senior Secured Convertible Notes | -$3.3M-811.9% | $462K+107.7% | -$6.0M-373.4% | -$1.3M | |||||||||||||
| Debt extinguishments loss - Senior Secured Convertible Notes | -$58K+97.7% | -$2.5M+33.0% | -$3.8M+30.4% | -$5.4M | |||||||||||||
| Debt modification expense | $0+100.0% | -$2.0M | — | — | |||||||||||||
| Management fee income | $13.8M+257.8% | $3.9M | — | — | |||||||||||||
| Grant income | $416K+281.7% | $109K | — | — | |||||||||||||
| Other income (expense), net | $19.3M-73.5% | $72.9M+796.5% | -$10.5M+13.9% | -$12.2M | |||||||||||||
| Income (loss) before provision for income tax | -$2.5M-108.7% | $28.4M+135.9% | -$79.3M+23.2% | -$103.2M | |||||||||||||
| Provision for income taxes | $0 | $0 | — | — | |||||||||||||
| Net income (loss) before noncontrolling interests | -$2.5M-108.7% | $28.4M+135.9% | -$79.3M+23.2% | -$103.2M | |||||||||||||
| Net loss attributable to the noncontrolling interests | $2.9M-74.7% | $11.4M-24.7% | $15.1M+5.8% | $14.3M | |||||||||||||
| Net income (loss) attributable to PAVmed Inc. | $401K-99.0% | $39.8M+162.0% | -$64.2M+27.9% | -$89.0M | |||||||||||||
| Net income (loss) attributable to PAVmed Inc. common stockholders | -$3.8M-111.8% | $32.0M+148.2% | -$66.3M+25.8% | -$89.3M | |||||||||||||
| Net income (loss) per share attributable to PAVmed Inc. common stockholders – basic (in dollars per share) | -$5.63-105.7% | $99.15+1182.4% | -$9.16+39.1% | -$15.03 | |||||||||||||
| Net income (loss) per share attributable to PAVmed Inc. common stockholders – diluted (in dollars per share) | -$5.63-137.8% | $14.90+262.7% | -$9.16+39.1% | -$15.03 | |||||||||||||
| Weighted average common shares outstanding, basic (in shares) | 670.5M+108.0% | 322.4M-95.5% | 7.23B+21.8% | 5.94B | |||||||||||||
| Weighted average common shares outstanding, diluted (in shares) | 670.5M-69.2% | 2.17B-69.9% | 7.23B+21.8% | 5.94B | |||||||||||||
| Series B Preferred Stock [Member] | |||||||||||||||||
| Less: Preferred Stock dividends earned | -$1.8M-442.2% | -$329K-8.2% | -$304K-8.2% | -$281K | |||||||||||||
| Series C Preferred Stock [Member] | |||||||||||||||||
| Less: Deemed dividend | -$2.0M+72.9% | -$7.5M | — | — | |||||||||||||
| Subsidiary Preferred Stock [Member] | |||||||||||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.